Bringout the Health Within

CLINICAL STUDIES ON OSCILLOCOCCINUM

Oscillococcinum has been shown in clinical trials to help reduce the severity and shorten the duration of flu-like symptoms.1,2

1FERLEY STUDY
Ferley JP, Zmirou D, D’Adhemar D, Balducci F. A controlled evaluation of a homeopathic preparation in the treatment of influenza-like syndromes. Br J Clin Pharmacol. 1989;27:329-335.

  1. A controlled clinical trial was conducted to assess the effectiveness of a homeopathic preparation in the treatment of influenza-like syndromes.
  2. 237 cases received the test drug and 241 were assigned to placebo. Patients recorded their rectal temperature twice a day, and the presence or absence of five cardinal symptoms (headache, stiffness, lumbar and articular pain, shivers) along with cough, coryza and fatigue.
  3. Recovery was defined as a rectal temperature less than 37.5°C and complete resolution of the five cardinal symptoms.
  4. The proportion of cases who recovered within 48h of treatment was greater among the active drug group than among the placebo group (17.1% against 10.3%, P = 0.03).
  5. The result cannot be explained given our present state of knowledge, but it calls for further rigorously designed clinical studies.

2PAPP STUDY
Papp R, Schuback G, Beck E, et al. Oscillococcinum in patients with influenza-like syndromes: a placebo-controlled, double-blind evaluation. Br Homeopath J. 1998;87:69-76.

A controlled clinical trial was conducted to assess the effectiveness of Oscillococcinum® in the treatment of patients with influenza-like syndromes. 188 patients received the test drug and 184 patients were assigned to the placebo. Data were recorded by the participating physicians at the beginning of the treatment, after 48 hours and after 7-10 days. During the first few days, the patients recorded their rectal temperature twice a day (mornings and evenings), 9 symptoms on a rating scale (cough, catarrh, sore throat, muscle pain, etc.) and use of medication. Recovery was defined as follows: ‘rectal temperature ˂37.5°C and no headache or muscle pain’. Effectiveness was defined as a statistically significant greater decrease in symptoms after 48 hours in the verum group or a shorter duration of symptoms in comparison to the placebo group. After 48 hours the symptoms of the patients in the verum group were significantly milder (P = 0.023) than in the placebo group. The number of patients with no symptoms was significantly higher in the verum group from the second day onwards (verum: 17.4%, placebo: 6.6%) until the end of the patients’ recording (day 5 in the evening: verum: 73.7%, placebo: 67.7%). The biggest group difference was recording for the time between the evening of the second day (10.6% more patients with no symptoms) and the morning of the fourth day (10.2% more patients with no symptoms). The clinical trial showed that treatment of influenza-like syndromes with Oscillococcinum® has a positive effect on the decline of symptoms and on the duration of the disease.